Company: OSRH
Filing Date: 2025-04-22
Form Type: 10-K
Source: 0001213900-25-034116
Chunk: 45

Company: OSR Holdings, Inc.
Filing Date: 2025-04-22
Form: 10-K
Item: Item 1
Chunk 45
---
Our product candidates, if any are approved, may compete with these existing drug and other therapies.

The table below summarizes the main competitors we have identified
for Vaximm’s VXM01. Each of these identified competitors are developing therapies for glioblastoma and have active clinical trials
ongoing assessing the safety and efficacy of their product candidates.

    Drug Name
     
    Company
     
    Mechanism
     
    Indication
     
    Clinical
Phase
     
    NCT
Number(s)
  
    Depatuxizumab mafodotin (ABT-414)
     
    AbbVie
     
    Antibody-drug conjugate targeting EGFR
     
    Newly diagnosed glioblastoma
     
    Phase 2/3
     
    NCT02573324
  
    Durvalumab (MEDI4736)
     
    AstraZeneca
     
    PD-L1 checkpoint inhibitor
     
    Newly diagnosed and recurrent glioblastoma
     
    Phase 2
     
    NCT02336165
  
    Regorafenib
     
    Bayer
     
    Multi-kinase inhibitor
     
    Recurrent glioblastoma
     
    Phase 2
     
    NCT02926222
  
    Tasadenoturev( DNX-2401)
     
    DNAtrix
     
    Oncolytic adenovirus
     
    Recurrent glioblastoma
     
    Phase 2
     
    NCT03178032
  
    Ofranergene obadenovec (VB-111)
     
    VBL Therapeutics
     
    Dual-targeted gene therapy
     
    Recurrent glioblastoma
     
    Phase 3
     
    NCT02511405
  
    AV-GBM-1
     
    Aivita Biomedical
     
    Personalized dendritic cell vaccine
     
    Newly diagnosed glioblastoma
     
    Phase 2
     
    NCT03400917
  
    VAL-083
     
    Kintara Therapeutics
     
    DNA-targeting agent
     
    Recurrent and newly diagnosed glioblastoma
     
    Phase 2/3
     
    NCT02717962, NCT030507